AbbVie Inc (ABBV)vsAgnico Eagle Mines Limited (AEM)
ABBV
AbbVie Inc
$201.55
-0.57%
HEALTHCARE · Cap: $358.55B
AEM
Agnico Eagle Mines Limited
$193.21
+2.90%
BASIC MATERIALS · Cap: $93.89B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 364% more annual revenue ($62.82B vs $13.54B). AEM leads profitability with a 39.5% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.57. AEM earns a higher WallStSmart Score of 75/100 (B+).
ABBV
Buy63
out of 100
Grade: C+
AEM
Strong Buy75
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-20.5%
Fair Value
$168.19
Current Price
$201.55
$33.36 premium
Margin of Safety
-12.6%
Fair Value
$192.97
Current Price
$193.21
$0.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Keeps 40 of every $100 in revenue as profit
Strong operational efficiency at 62.8%
Revenue surging 66.1% year-over-year
Earnings expanding 108.6% YoY
Conservative balance sheet, low leverage
Large-cap with strong market position
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : AEM
The strongest argument for AEM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 39.5% and operating margin at 62.8%. Revenue growth of 66.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : AEM
The primary concerns for AEM are PEG Ratio.
Key Dynamics to Monitor
ABBV profiles as a value stock while AEM is a growth play — different risk/reward profiles.
AEM carries more volatility with a beta of 0.57 — expect wider price swings.
AEM is growing revenue faster at 66.1% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
AEM scores higher overall (75/100 vs 63/100), backed by strong 39.5% margins and 66.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Agnico Eagle Mines Limited
BASIC MATERIALS · GOLD · USA
Agnico Eagle Mines Limited is engaged in the exploration, development and production of mineral properties in Canada, Sweden and Finland. The company is headquartered in Toronto, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?